Optimizing drug development for the next generation of Alzheimer's disease compounds

Alzheimer's Reports

Volumn 1, Issue 5, 1998, Pages 285-290

  Cutler, Neal R ^a   Sramek, John J ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 22444453791     PISSN: 14616130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Anand R, Gharabawi G and Enz A (1996). Efficacy and safety results of the early phase studies with Exelon® (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 8, 109-116.
2. Anand R and Hartman R (1996). Strategies for the optimal development of an anti-dementia drug. Presented at the Fifth International Conference on Alzheimer's Disease and Related Disorders, July 24-29; Osaka, Japan.
3. Bodick NC, Offen WW, Levey AI et al. (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 54, 465-473.
4. Cutler NR, Jhee SS, Cyrus P et al. (1998a). Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci 62, 1433-1441.
5. Cutler NR, Murphy MF, Nash RJ, Prior PL and De Luna DM (1990). Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1 -oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. J Clin Pharmacol 30, 556-561.
6. Cutler NR, Polinsky RJ, Sramek JJ et al. (1998b). Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 97, 244-250.
7. Cutler NR and Sramek JJ (1995). Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 48, 421-428.
8. Cutler NR and Sramek JJ (1998). Guidelines for conducting bridging studies in Alzheimer's disease. Alzheimer Dis Assoc Disord 12(2), 88-92.
9. Cutler NR, Sramek JJ, Greenblatt DJ et al. (1997a). Defining the maximum tolerated dose: investigator, academic, industry, and regulatory perspectives. J Clin Pharmacol 37, 767-783.
10. Cutler NR, Sramek JJ and Kilborn JR (1996). The bridging concept: optimizing the dose for phase II/III in Alzheimer's disease. Neurodegeneration 5(4), 511-514.
11. Cutler NR, Sramek JJ and Vroff AE (1994). Alzheimer's Disease: Optimizing Drug Development Strategies. Chichester, John Wiley & Sons.
12. Medina A, Bodick N, Goldberger AL, MacMahon M and Lipsitz LA (1997). Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension 29, 828-834.
13. Peck CC, Barr WH, Benet LZ et al. (1994). Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Clin Pharmacol 34, 111-119.
14. Puri SK, Ho I, Hsu R and Lassman HB (1990). Multiple-dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. J Clin Pharmacol 30(10), 948-955.
15. Reece PA, Bockbrader H and Sedman AJ (1992). Safety, pharmacodynamics, and pharmacokinetics of a new muscarinic agonist, CI-979. Clin Exp Pharmacol Physiol 21(Suppl), 58.
16. Sramek JJ, Anand R, Wardle TS et al. (1996). Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 58, 1201-1207.
17. Sramek JJ, Block GA, Reines SA et al. (1995a). A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 56(5), 319-326.
18. Sramek JJ, Forrest M, Mengel H et al. (1997). A bridging study of Lu 25-109 in patients with probable Alzheimer's disease. Life Sci 62, 195-202.
19. rd Annual Meeting of the Society of Biological Psychiatry. Toronto, Canada, May 27-31.
20. Sramek JJ, Hurley DJ, Wardle TS et al. (1995c). The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 35, 800-806.
21. Sramek JJ, Sedman AJ, Reece PA et al. (1995b). Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 57, 503-510.
22. Veroff AE, Cutler MR, Sramek JJ et al. (1991). A new assessment tool for neuropsychopharmacologic research: the computerized neuropsychological test battery (CNTB). J Geriatr Psychiat Neurol 4, 211-217.
23. Weissman L (1981). Multiple-dose phase I trials - normal volunteers or patients? One viewpoint. J Clin Pharmacol 21, 385-387.